Warner-Lambert's Eryc
Executive Summary
Oral antibiotic has captured 28% of $130 mil. U.S. erythromycin market to become the market leader with approximately $36 mil. in U.S. sales, according to F. H. Faulding, the Australian firm that licenses the drug to Parke-Davis. Faulding also reports that sales of oral doxycycline Doryx have reached $5.5 mil. in the U.S. since the product was launched in February. Doryx is also licensed to Warner-Lambert.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.